Quick Facts: Uses of Koliva

• Primary Indication: Management of primary biliary cholangitis (PBC).
• Patient Population: Adults who have had an inadequate response to or cannot tolerate ursodeoxycholic acid (UDCA).
• Therapeutic Goal: May improve certain liver function blood tests.

---

Koliva (generic name: obeticholic acid) is a prescription medicine approved for the treatment of primary biliary cholangitis (PBC) in adult patients. PBC is a chronic liver condition that may progress over time. Koliva is used as an adjunctive therapy, meaning it is often administered alongside ursodeoxycholic acid (UDCA) for individuals who have not achieved an adequate response to UDCA therapy alone.

The medication may also be an appropriate option for those adults who have a documented intolerance to UDCA. The primary goal of treatment is to help improve certain blood markers of liver function, such as alkaline phosphatase (ALP), in the target patient population. A decrease in these markers is generally associated with the management of the condition.

Koliva is an established medication with therapeutic uses for specific PBC patients who do not have advanced cirrhosis. It is important for patients to receive regular monitoring by a healthcare professional throughout the course of treatment.

Eligibility Map: Who Can and Cannot Use Koliva — Official Regulatory Information

The official regulatory profile for Koliva (obeticholic acid) defines eligibility based on a patient's liver disease severity, age, and physiological status.

Category	Eligibility Rules as Documented in Regulatory Sources
Populations for whom use is allowed	Adult patients (age 18 and older) with Primary Biliary Cholangitis (PBC) who have had an inadequate response to or cannot tolerate ursodeoxycholic acid (UDCA).
Populations for whom use is contraindicated	Patients with complete biliary obstruction; those with decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event; and those with compensated cirrhosis who show evidence of portal hypertension.
Age-related eligibility rules	Use is not established for PBC in pediatric patients. The medicine is contraindicated in children with biliary atresia and other chronic cholestatic liver diseases.
Condition-specific eligibility rules	Use in patients with compensated cirrhosis requires close routine monitoring. Patients with pre-existing moderate or severe hepatic impairment require a specific, restricted starting schedule.
Pregnancy and lactation status	Use during pregnancy is generally restricted and avoided due to limited data. Use is not recommended during lactation.

Eligibility Classifications (High-Level)

Eligibility severity classification	Contraindicated, Restricted Use, Not Recommended, Use Not Established
Regulatory basis	U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Connection to the overall eligibility profile: Regulatory documents establish that Koliva is primarily eligible for adults with PBC whose condition meets specific criteria regarding UDCA response and liver function. Eligibility is strictly limited by the presence of advanced liver disease, with absolute contraindications applied to patients with complete biliary obstruction or decompensated cirrhosis. The profile restricts use in specific age groups and physiological states, such as certain pediatric patients and women who are pregnant or breastfeeding.

Koliva (Obeticholic Acid) has several officially documented interactions that primarily relate to its absorption and its effect on the systemic levels of co-administered medicines.

Interaction Classification and Constraints

Classification Type	Official Regulatory Statement
Interaction Severity	Contraindicated (with Biliary Obstruction/Decompensated Cirrhosis); Clinically Significant (with specific drugs)
Interaction-context Constraints	Mandatory timing separation; Required therapeutic monitoring

Official Interaction Statements

Bile Acid Binding Resins, such as cholestyramine, colestipol, or colesevelam, significantly reduce the absorption and efficacy of Koliva. To mitigate this effect, Koliva must be administered at least 4 to 6 hours before or 4 to 6 hours after taking the resin.

Koliva may increase the exposure of certain medicines, particularly CYP1A2 substrates with a narrow therapeutic index (e.g., theophylline, tizanidine). Therapeutic monitoring is recommended for these combinations. The International Normalized Ratio (INR) is decreased following co-administration with Warfarin, requiring INR monitoring and dosage adjustment.

Concomitant use with Inhibitors of Bile Salt Efflux Pump (BSEP), such as cyclosporine, should be avoided due to the risk of increased obeticholic acid accumulation. Additionally, Koliva is contraindicated in patients with Complete Biliary Obstruction and in those with Decompensated Cirrhosis or a prior decompensation event, a constraint tied to the risk of serious liver injury.

Koliva is an agonist of the Farnesoid X Receptor (FXR), a nuclear receptor highly expressed in hepatocytes within the liver and enterocytes within the intestine.

Upon binding, Koliva activates FXR, initiating a cascade that modulates gene expression integral to bile acid homeostasis and inflammation. Intracellularly, FXR activation upregulates the expression of the transcriptional repressor Small Heterodimer Partner (SHP). SHP then suppresses the transcription of the enzyme Cholesterol 7-alpha-hydroxylase (CYP7A1), a rate-limiting enzyme in the de novo synthesis of bile acids from cholesterol. This suppression limits the overall intrahepatic production of bile acids.

Concurrently, FXR activation increases the expression of bile acid transporters, such as the Bile Salt Export Pump (BSEP), which facilitates the efflux of bile acids from hepatocytes into the bile canaliculi. The combined molecular and intracellular effects of decreased synthesis and enhanced efflux lead to a reduction in the total concentration of bile acids within the hepatocyte pool. System-level physiological modulation involves a net decrease in the circulating bile acid pool and promotion of choleresis.

Koliva, which contains the active substance obeticholic acid, is administered as an oral tablet for the treatment of Primary Biliary Cholangitis (PBC). The dosing regimen is strictly dependent on the patient's liver status.

---

Official Dosing and Titration Schedules

Patient Classification	Starting Dose	Maximum Dose and Titration
Non-Cirrhotic or Compensated	5 mg once daily	Increase to 10 mg once daily after 3 to 6 months if response is inadequate and the dose is tolerated.
Moderate/Severe Hepatic Impairment	5 mg once weekly	May be titrated up to 10 mg twice weekly (doses separated by 3 days) based on response and tolerability.

---

Administration Requirements

Koliva may be taken with or without food. If the medicine is taken concurrently with a bile acid binding resin (e.g., cholestyramine), Koliva must be administered at least 4 hours before or 4 to 6 hours after the resin, or separated by the greatest possible interval.

If a dose is missed, the official instruction is to skip the missed dose and resume the next scheduled dose; a double dose should not be taken. For administration-related issues, such as intolerable pruritus, the dosing frequency may be reduced (e.g., to 5 mg every other day) or the treatment may be temporarily interrupted for up to two weeks, followed by a restart at a reduced dosage. No dosage adjustment is generally required for older adults or in patients with renal impairment.

Research evidence / Overview of studies for Koliva (Obeticholic Acid)

Koliva was studied for use in adult patients with Primary Biliary Cholangitis (PBC), specifically in those whose condition demonstrated an inadequate response to the standard first-line medication, ursodeoxycholic acid (UDCA). The most crucial evidence comes from short-term, randomized controlled trials (RCTs). These studies compared Koliva to a placebo (an inactive substance) over a defined period, typically 12 months.

The primary goal of this research was to evaluate the effects on biochemical surrogate endpoints. These measurements are classified as surrogate endpoints, used in research exploring whether changes in their levels are associated with long-term clinical outcomes, acknowledging they are not direct measures of survival or complications. Research describes patterns of measurement change in these blood markers among patients receiving Koliva, compared to those receiving the placebo.

Key Study Outcomes and Endpoints

The main short-term research centered on tracking the achievement of a composite biochemical response, a specific target based on meeting defined criteria for Alkaline Phosphatase (ALP) and Total Bilirubin (TB) levels. Long-term follow-up studies, which continued to monitor patients from the initial trials, studies monitored outcomes related to systemic or functional imbalance, such as time to liver transplant, liver-related death, or serious hepatic complications. This extended research contributes to the broader evidence landscape by looking at clinical events that take many years to occur.

Unanswered Questions and Research Gaps

Despite the available evidence, several aspects of Koliva's long-term use and research remain uncertain. The full extent of long-term effects are not fully established based on highly controlled RCTs that last for decades. Furthermore, direct comparative evidence is limited for Koliva against other established second-line therapies for PBC, as the focus of the pivotal trials was mainly on comparison with placebo in the UDCA non-responder population. Evidence remains limited for specific populations such as children or pregnant individuals, and the results apply only to the populations studied in the major trials. Research is ongoing to continue monitoring and characterizing the long-term clinical patterns associated with Koliva use.

Key Studies & References

1. Clinical Review Report: Obeticholic Acid (Ocaliva): POISE Trial Primary Outcome

Common questions about Koliva (FAQ)

---

Q: How quickly should someone expect to feel effects after starting Koliva?

A: Official information indicates that Koliva can begin to work relatively quickly. It starts to work after approximately 1 hour, and the drug label describes symptom relief potentially being noticeable within 1 to 3 hours after administration.

---

Q: How long does the effect of Koliva last in the body?

A: The drug is formulated to provide sustained relief. The duration of the effect for the modified-release form is described as supporting a reduced daily administration schedule. The active substance, Mebeverine, is rapidly and completely broken down (metabolized) in the body.

---

Q: Does Koliva interact with alcohol?

A: According to the official product information and regulatory studies, no interaction has been demonstrated between Koliva (Mebeverine Hydrochloride) and alcohol (ethanol). Official information indicates that patients can generally eat and drink normally while using the medicine.

---

Q: Are there any foods or drinks that should be avoided with Koliva?

A: Official information states that patients can generally eat and drink normally while using Koliva. There are no specific food or beverage items described in the product label as needing to be avoided.

---

Q: Are there any specific activities to avoid while taking Koliva?

A: Official information states that Koliva is not likely to affect a patient's ability to drive or safely use tools or machinery. Official information suggests that patients' ability to perform these activities is not likely to be affected.

---

Q: Does Koliva interfere with hormonal birth control?

A: Regulatory sources state that Koliva is not known to affect the effectiveness of hormonal contraception. This includes the combined oral contraceptive pill and the progestogen-only pill.

---

Q: Are there any common supplements that are known to interact with Koliva?

A: The safety of taking Koliva alongside complementary, herbal remedies, or general supplements has not been fully established. This is because these products are typically not tested for drug-drug interactions in the same rigorous way as prescription medicines.

---

Q: Can taking Koliva affect results from a blood test?

A: Official literature describes that Koliva may, on rare occasions, affect the result of a urine drug-screening test. It has been reported to cause a false positive result for substances such as amphetamines in this type of test.

---

Q: Can Koliva cause changes in mood or sleep patterns?

A: Reported side effects listed in official documents include changes to sleep and mood. Specifically, insomnia (trouble sleeping) and depression have been reported as side effects of Koliva.

---

Q: Does Koliva cause weight gain or loss?

A: Based on regulatory-aligned product information, Koliva is not described as causing weight gain or weight loss.

---

Q: Is it normal to feel [vague side effect like 'tired'] when first using Koliva?

A: Yes, tiredness (or malaise) is described as a reported side effect in some official documents. This is a descriptive fact from the drug label, and any effects experienced should be discussed with a healthcare provider.

---

Q: Are the side effects of Koliva permanent?

A: Most reported side effects are described as mild and generally resolve as the body adjusts to the medication. Severe side effects, which are rare, may require medical guidance.

---

Q: Is Koliva associated with an increased risk of infections?

A: The official list of commonly reported adverse reactions for Koliva does not include an increased risk of infections.

---

Q: Why does the Koliva leaflet mention a risk of [common serious side effect]?

A: Regulatory patient leaflets are required to list all known potential reactions, including rare and serious risks. This ensures that regulatory communication covers potential reactions associated with the medicine.

---

Q: Can I stop taking Koliva abruptly if I feel better?

A: Regulatory guidance advises patients not to stop using Koliva without first speaking to a healthcare provider. This caution is given because stopping the medication without medical guidance can lead to unforeseen changes.

---

Q: Why is Koliva only available by prescription?

A: Koliva is classified as a prescription-only medicine (POM) in many countries. This is typically due to its intended use, which is for patients who have received a formal medical diagnosis, such as Irritable Bowel Syndrome (IBS), which requires professional management.

---

Q: Is Koliva considered a Schedule [X] controlled substance?

A: Koliva (Mebeverine Hydrochloride) is classified as a musculotropic antispasmodic. It is not classified as a controlled substance in major regulatory jurisdictions.

---

Q: Why is Koliva sometimes mentioned in discussions about [related condition]?

A: Official regulatory documents describe Koliva’s use for treating symptoms of Irritable Bowel Syndrome (IBS) and similar conditions involving gut overactivity. This includes chronic irritable colon, spastic constipation, and spastic colitis.

---

Q: Does Koliva need to be stored in the refrigerator?

A: No, Koliva should not be stored in a refrigerator. The official storage instruction is to keep the tablets at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F).

---

Q: What research is currently being done on Koliva?

A: Studies and official information indicate that research continues to monitor the drug’s long-term effects and general profile in the patient populations studied for its approved use.

---

Q: Is there any research evidence on Koliva's long-term safety?

A: Regulatory documents and systematic reviews describe that Koliva is generally well-tolerated with a good safety profile. This assessment is based on the studies conducted for its approved use in Irritable Bowel Syndrome (IBS).

---

Q: What is the half-life of Koliva?

A: The term 'half-life' describes how long it takes for half of a substance to leave the body. Koliva (Mebeverine) is rapidly and completely broken down (metabolized) upon absorption, and the active drug itself is not excreted. Its metabolic byproducts are largely excreted through the urine.

Storage and Disposal of Koliva (Obeticholic Acid)

Koliva tablets must be stored according to official regulatory specifications to maintain product integrity.

Storage Requirements

Requirement	Official Regulatory Statement
Temperature	Store at controlled room temperature, between 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are permitted.
Protection	Keep the medicine in the original container to protect it from moisture and light.
Child Safety	It must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Koliva should be disposed of properly. Regulatory guidance advises using an authorized drug take-back program where available. If a take-back program is not accessible, the product should be mixed with an unappealing substance, placed in a sealed container, and then discarded in the household trash. The medication must not be disposed of via wastewater or sewage.